Were Eli Lilly Unaware of This Study?

Were Eli Lilly Unaware of This Study?

Richard Hockey Because of the nature of the analysis used in this study [1], no conclusion is possible. There are plenty of examples in the literature demonstrating the “ecological fallacy”. Studies such as this have very little utility other than to generate hypotheses. I tend to think that this association is a marker for greater recognition and treatment for depression. However, it’s a brave...

Surviving sepsis--practice guidelines, marketing campaigns, and Eli Lilly.

Dr. Milstein is the chief physician at Mercer Health and Benefits and medical director of the Pacific Business Group on Health — both in San Francisco. Dr. Smith is the president and chief executive officer of the California HealthCare Foundation, Oakland, CA. Wachter RM. The “dis-location” of U.S. medicine — the implications of medical outsourcing. N Engl J Med 2006;354:661-5. The globalizatio...

Comments of Eli Lilly and Company on the Revised Interim Written Description Guidelines

Eli Lilly and Company (" Lilly ") is pleased to offer the following comments regarding the Patent and Trademark Office's ("PTO's") recently published Revised Interim Guidelines for Examination of Patent Applications Under the 35 U.S.C. Sec. 112, ¶ 1 "Written Description" Requirement (" the Guidelines ") and the accompanying training materials entitled Synopsis of Application of Written Descript...

Eli Lilly EL-468, a New Bait Toxicant for Control of the Red Imported Fire Ant

Eli Lilly EL-468, a phenylenediamine, possesses the delayed-toxicity necessary for a bait toxicant to control colonies of the red imported fire ant, Solenopsis invicta Buren. In laboratory tests it gave delayed action over more than a 10-fold range of concentrations; in field tests, baits formulated on pregel defatted corn grits and applied at 20 and 40 g AI/ha produced as high as 86 and 91% co...

Encouraging further innovation: Ariad v. Eli Lilly and the written description requirement.